Diagnostic Value of CircRNA-Uck2 for Acute Myocardial Infarction
NCT ID: NCT03170830
Last Updated: 2017-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
178 participants
INTERVENTIONAL
2015-08-01
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Recently, the investigators identified microarray analysis and real-time polymerase chain reaction (PCR) from AMI animal models and small samples of AMI patients, a molecular signature of AMI involving 5 circRNAs (circRNA\_006877, circRNA\_015350, circRNA\_002969, circRNA\_013240, circRNA\_004682) was found significantly change in AMI patients and likely serves as candidate serum biomarkers of AMI. Among the 5 circRNAs, circRNA\_006877 name of circRNA-Uck2 (cUck2) has more close association with AMI.
TYPE OF STUDY : multicenter diagnostic evaluation Study MAIN PURPOSE OF THE STUDY : To evaluate the diagnostic value of circRNAs in AMI in adults as compared to healthy and unstable angina controls
SECONDARY OBJECTIVES :
assess the ability of cUck2 to discriminate a AMI disease from unstable angina patients in adults.
explore the relationship between cUck2 and heart function after myocardial infarction PRODUCTS OF THE STUDY diagnostic kit of AMI in quantitative polymerase chain reaction (qPCR) NUMBER OF PATIENTS : 3 groups with 169 patients will be included Group 1: 66 AMI adult patients Group 2: 56 unstable angina adults Group 3: 56 Witnesses healthy adults INCLUSION LENGTH 36 months DURATION OF THE STUDY 42 months
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy control group
Age:45-75 years.Pepole who have normal ECG without the history of cardiovascular disease can be included in the healthy control group.
the diagnosis value of cUck2 in acute myocardial infarction.
Collect blood at different time points and compare cUck2 in three groups.
unstable angina disease control group
Age:\>18 years.Unstable angina patients meet the diagnostic criteria.
the diagnosis value of cUck2 in acute myocardial infarction.
Collect blood at different time points and compare cUck2 in three groups.
acute myocardial infarction group
Age:\>18 years.Acute myocardial infarction patients meet the diagnostic criteria.
the diagnosis value of cUck2 in acute myocardial infarction.
Collect blood at different time points and compare cUck2 in three groups.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
the diagnosis value of cUck2 in acute myocardial infarction.
Collect blood at different time points and compare cUck2 in three groups.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute Myocardial Infarction Group:Clinical diagnosis of acute myocardial infarction
* Unstable Angina Group:Clinical diagnosis of unstable angina.
* Sign informed consent.
Exclusion Criteria
* Malignant hypertension, severe arrhythmia.
* Chronic muscle disorders, rhabdomyolysis.
* Severe liver and kidney dysfunction.
* Malignant tumors, acute cerebrovascular disease.
* Severe neurosis, psychosis.
* Patients who had any of the above were excluded.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Fangshan District Liangxiang Hospital
OTHER
Beijing Haidian Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hong-Jin Wu
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hong-Jin Wu
Role: STUDY_DIRECTOR
Beijing Haidian Hospital,Haidian Section of Peking University Third Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Haidian Hospital, Haidian Section of Peking University Third Hospital
Beijing, China/Beijing, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hong-Yun Wang
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Danese E, Montagnana M. An historical approach to the diagnostic biomarkers of acute coronary syndrome. Ann Transl Med. 2016 May;4(10):194. doi: 10.21037/atm.2016.05.19.
Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A. 1976 Nov;73(11):3852-6. doi: 10.1073/pnas.73.11.3852.
Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013 Feb;19(2):141-57. doi: 10.1261/rna.035667.112. Epub 2012 Dec 18.
Suzuki H, Zuo Y, Wang J, Zhang MQ, Malhotra A, Mayeda A. Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing. Nucleic Acids Res. 2006 May 8;34(8):e63. doi: 10.1093/nar/gkl151.
Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, Kohlmaier A, Herbst A, Northoff BH, Nicolaou A, Gabel G, Beutner F, Scholz M, Thiery J, Musunuru K, Krohn K, Mann M, Teupser D. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun. 2016 Aug 19;7:12429. doi: 10.1038/ncomms12429.
Wang K, Long B, Liu F, Wang JX, Liu CY, Zhao B, Zhou LY, Sun T, Wang M, Yu T, Gong Y, Liu J, Dong YH, Li N, Li PF. A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223. Eur Heart J. 2016 Sep 1;37(33):2602-11. doi: 10.1093/eurheartj/ehv713. Epub 2016 Jan 21.
Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Just S, Borries A, Rudloff J, Leidinger P, Meese E, Katus HA, Rottbauer W. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol. 2011 Jan;106(1):13-23. doi: 10.1007/s00395-010-0123-2. Epub 2010 Oct 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KYZ2017001
Identifier Type: -
Identifier Source: org_study_id